Vivakor Confirms Record Date of Stock Dividend
04 Diciembre 2009 - 1:09PM
PR Newswire (US)
CORALVILLE, Iowa, Dec. 4 /PRNewswire-FirstCall/ -- Vivakor, Inc.
(OTC Bulletin Board: VIVK) today confirmed that its shareholders of
record on December 1, 2009 will receive the dividend of shares of
common stock of HealthAmerica, Inc. that was previously approved by
Vivakor's Board of Directors. HealthAmerica is a private Nevada
corporation of which Vivakor owned approximately 84% of the
outstanding common shares on the record date. The distribution date
is still expected to be December 9, 2009. Each Vivakor shareholder
will be entitled to receive one share of HealthAmerica common stock
for each share of Vivakor common stock beneficially owned on
December 1, 2009. After the dividend distribution, Vivakor will
continue to own approximately 62% of the outstanding common stock
of HealthAmerica. Vivakor shareholders will not be required to take
any action to receive the HealthAmerica common shares on the
distribution date. About Vivakor, Inc. Vivakor(TM) is a
biomedical/biotechnology company with transdisciplinary research
that develops and acquires products in the fields of molecular
medicine, electro-optics, biological handling and natural and
formulary compounds, that extend or improve life. More information
can be found about Vivakor at http://www.vivakor.com/. About
HealthAmerica, Inc. HealthAmerica is developing a patented, FDA
510(k) cleared, technology (VIVASlices(TM) that is expected to
enhance the resolution of images resulting from MRI. The underlying
algorithm may also be useful in determining blood flow velocity
measures in imaged tissues, which would be valuable in accessing
areas of blood flow constriction from plaques or other hematologic
deposits. This information could help physicians better diagnose,
predict and assess stroke and related diseases involving blood flow
obstruction. At the end of 2000, there were approximately 9,500 MRI
(magnetic resonance imaging) systems installed worldwide. While
changes in medical reimbursements have slowed the sale of new
machines, there is an increased demand for improved efficiency
(i.e. accelerated patient throughput) from current systems.
Additionally, intense competition between various medical
facilities and the rapid distribution of new advances in imaging
(such as MR angiographies, which allow evaluation of blood vessels
without any invasive procedure) puts additional pressure on MRI
because increased image quality requires additional time. Thus
there is a huge need for an application like VIVASlices that can
improve both throughput and image quality. FORWARD-LOOKING
STATEMENTS This press release may contain forward-looking
statements, including, but not limited to, statements regarding
Vivakor's and HealthAmerica's products and markets. Forward-looking
statements may be identified by the use of the words "anticipates,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"will," "believes," "estimates," "potential," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in Vivakor's filings
with the Securities and Exchange Commission, which factors are
incorporated herein by reference. Readers are cautioned not to
place undue reliance on any of these forward-looking statements.
Vivakor undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this press release or to reflect actual outcomes.
Contact: Vivakor, Inc. Matt Nicosia, 319-625-2172 DATASOURCE:
Vivakor, Inc. CONTACT: Matt Nicosia, Vivakor, Inc.,
+1-319-625-2172, Web Site: http://www.vivakor.com/
Copyright